Trial Profile
The Safety and Efficacy Evaluation of CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 14 Apr 2017 Status changed to recruiting.
- 08 Jul 2016 New trial record